- Home
- FAMI vs DRMA Comparison
FAMI vs DRMA Comparison
Compare FAMI & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- DRMA
- Stock Information
- Founded
- FAMI 2015
- DRMA 2014
- Country
- FAMI China
- DRMA United States
- Employees
- FAMI N/A
- DRMA N/A
- Industry
- FAMI Packaged Foods
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- FAMI Consumer Staples
- DRMA Health Care
- Exchange
- FAMI Nasdaq
- DRMA Nasdaq
- Market Cap
- FAMI 2.1M
- DRMA 2.1M
- IPO Year
- FAMI 2018
- DRMA 2021
- Fundamental
- Price
- FAMI $1.56
- DRMA $2.45
- Analyst Decision
- FAMI
- DRMA Strong Buy
- Analyst Count
- FAMI 0
- DRMA 1
- Target Price
- FAMI N/A
- DRMA $10.00
- AVG Volume (30 Days)
- FAMI 10.5K
- DRMA 48.6K
- Earning Date
- FAMI 01-26-2026
- DRMA 11-14-2025
- Dividend Yield
- FAMI N/A
- DRMA N/A
- EPS Growth
- FAMI N/A
- DRMA N/A
- EPS
- FAMI N/A
- DRMA N/A
- Revenue
- FAMI $43,831,754.00
- DRMA N/A
- Revenue This Year
- FAMI N/A
- DRMA N/A
- Revenue Next Year
- FAMI N/A
- DRMA N/A
- P/E Ratio
- FAMI N/A
- DRMA N/A
- Revenue Growth
- FAMI N/A
- DRMA N/A
- 52 Week Low
- FAMI $1.39
- DRMA $2.39
- 52 Week High
- FAMI $7.07
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- FAMI 37.93
- DRMA 23.81
- Support Level
- FAMI $1.40
- DRMA $2.95
- Resistance Level
- FAMI $1.58
- DRMA $3.13
- Average True Range (ATR)
- FAMI 0.06
- DRMA 0.21
- MACD
- FAMI 0.00
- DRMA -0.02
- Stochastic Oscillator
- FAMI 30.97
- DRMA 9.22
About FAMI Farmmi Inc.
Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.